Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback